02nd week of 2021 patent applcation highlights part 24 |
Patent application number | Title | Published |
20210009574 | Amine derivative and an organic electroluminescent device thereof - The present disclosure discloses an amine derivative and an organic electroluminescent device thereof, and relates to a technical field of organic photoelectric materials. The technical problem to be solved by the present disclosure is that the current light extraction material has poor thermal stability and the organic electroluminescent device has short service life. The amine derivative of the present disclosure is a diamine with a bridging group containing a fluorenyl group or a spirofluorenyl group, and the substituent group on N contains at least one benzoxazolyl group, benzothiazolyl group or benzimidazolyl group. The organic electroluminescent device of the present disclosure comprises an anode, an organic layer, a cathode and a light extraction layer, the organic layer is located between the anode and the cathode, and the light extraction layer comprises the amine derivative of Formula I according to the present disclosure. | 2021-01-14 |
20210009575 | HYDROXYISOXAZOLINES AND DERIVATIVES THEREOF - The present disclosure relates to the use of hydroxyisoxazolines and derivatives thereof as fungicide. It also relates to new hydroxyisoxazolines derivatives, their use as fungicide and compositions comprising thereof. | 2021-01-14 |
20210009576 | COMPOUNDS - The present invention relates to compounds of Formula I as defined herein, and salts and solvates thereof. (I) The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to compounds of Formula (I) for use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which inhibition of a RAS-effector protein-protein interaction is implicated. | 2021-01-14 |
20210009577 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME - Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers. | 2021-01-14 |
20210009578 | DISPOSABLE SENSOR CHIP WITH REAGENT INCLUDING 2-SUBSTITUTED BENZOTHIAZOLYL-3-SUBSTITUTED PHENYL-5-SUBSTITUTED SULFONATED PHENYL-2H-TETRAZOLIUM SALT - A disposable sensor chip for biological component concentration measurement includes: a chip main body defining a cavity through which a body fluid is flowable; and a reagent located in the cavity such that the body fluid flowing through the cavity comes into contact with the reagent. The reagent comprises a 2-substituted benzothiazolyl-3-substituted phenyl-5-substituted sulfonated phenyl-2H-tetrazolium salt. | 2021-01-14 |
20210009579 | PROCESSES FOR THE PREPARATION OF ARYL HYDROCARBON RECEPTOR LIGANDS - The present disclosure relates to the preparation of methyl 2-(1H-indole-3-carbonyl)thiazole-4-carboxylate (ITE) and related compounds with high yield, purity, and scalability. The processes apply the use of a Weinreb amide intermediate as a scaffold for the preparation of ITE and structural analogs. | 2021-01-14 |
20210009580 | AZTREONAM DERIVATIVES AND USES THEREOF - Disclosed herein are aztreonam derivatives, therapeutic methods of using the aztreonam derivatives, particularly in combination with β-lactamase inhibitors, and pharmaceutical compositions thereof. The aztreonam derivatives can be administered orally to provide orally bioavailable aztreonam. | 2021-01-14 |
20210009581 | ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT - The present invention concerns a compound of following general formula (I): | 2021-01-14 |
20210009582 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS - The present invention relates to bicyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR3 enzyme and are useful in the treatment of FGFR3-associated diseases such as cancer. | 2021-01-14 |
20210009583 | DEUTERATED IMIDAZOPYRIDINES - A series of imidazopyridine and pyrazolopyridine compounds is provided in which carbon hydrogen bonds have been replaced with isotopic carbon-deuterium bonds, syntheses thereof, compositions thereof, and methods of using such compounds and compositions. Various embodiments provide methods of killing and/or inhibiting the growth of | 2021-01-14 |
20210009584 | COMPOUND INCLUDING BENZIMIDAZOLE RING STRUCTURE AND ORGANIC ELECTROLUMINESCENT ELEMENT - A compound including a benzimidazole ring structure, represented by general formula (1). | 2021-01-14 |
20210009585 | HISTONE DEMETHYLASE INHIBITORS - The present invention relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyrido[3,4-d]pyrimidin-4-one derivative compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for inhibition of histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer, such as prostate cancer, breast cancer, bladder cancer, lung cancer and/or melanoma and the like. | 2021-01-14 |
20210009586 | DIHYDROINDOLIZINONE DERIVATIVE - A compound represented by general formula (I) (wherein all symbols are as defined in the description) or a salt, solvate, N-oxide form or prodrug thereof is a potent FXIa inhibitor, has excellent oral absorption properties and kinetics in blood, can exert a potent anti-coagulation activity over a long period of time after being administered orally, and has a discrepancy between the anti-coagulation activity thereof and the CYP-inhibiting activity thereof. Therefore, the compound or the salt, solvate, N-oxide form or prodrug thereof can be used as an efficient prophylactic and/or therapeutic agent for vascular occlusive diseases. | 2021-01-14 |
20210009587 | ERBB RECEPTOR INHIBITORS - Disclosed are compounds inhibiting ErbBs (e.g. HER2), pharmaceutically acceptable salts, hydrates, solvates or stereoisomers thereof and pharmaceutical compositions comprising the compounds. The compound and the pharmaceutical composition can effectively treat diseases associated ErbBs (especially HER2), including cancer. | 2021-01-14 |
20210009588 | NOVEL BENZYLAMINO SUBSTITUTED PYRIDOPYRIMIDINONES AND DERIVATIVES AS SOS1 INHIBITORS - The present invention encompasses compounds of formula (1) | 2021-01-14 |
20210009589 | BICYCLIC COMPOUNDS AS ATX INHIBITORS - The invention provides novel compounds having the general formula (I) | 2021-01-14 |
20210009590 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE - The present description relates to compounds, forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease. | 2021-01-14 |
20210009591 | PYRAZOLE DERIVATIVE COMPOUND AND USE THEREOF - Provided is a compound represented by Formula 1 having an inhibitory activity on lysine-specific demethylase-1 (LSD1), an optical isomer, a solvate, a tautomer, or a pharmaceutically acceptable salt thereof, which is effective in preventing or treating a disease caused by abnormal activation of LSD1. | 2021-01-14 |
20210009592 | ORGANIC COMPOUNDS - The invention relates to particular deuterated substituted heterocycle fused gamma-carbolines, in free, solid, pharmaceutically acceptable salt and/or substantially pure form as described herein, pharmaceutical compositions thereof, and methods of use in the treatment of diseases involving the 5-HT | 2021-01-14 |
20210009593 | PURINONE DERIVATIVE HYDROCHLORIDE - The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells. | 2021-01-14 |
20210009594 | 5-5 FUSED RINGS AS C5a INHIBITORS - The present disclosure provides, inter alia, Compounds of Formula (I) | 2021-01-14 |
20210009595 | PYRAZOLOPYRIMIDINE COMPOUNDS - The present teachings provide a compound represented by the following structural formula: (Formula (I)); or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof. | 2021-01-14 |
20210009596 | DIARYL SUBSTITUTED 5,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS - The present disclosure provides, inter alia, Compounds of Formula (I) | 2021-01-14 |
20210009597 | HETEROCYCLE COMPOUNDS AS TYRO3, AXL AND MERTK (TAM) FAMILY OF RECEPTOR TYROSINE KINASE INHIBITORS - Disclosed are compounds of formula (I) below and tautomers, stereoisomers, isotopologues, or pharmaceutically acceptable salts thereof: | 2021-01-14 |
20210009598 | PHTHALAZINE ISOXAZOLE ALKOXY DERIVATIVES, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF - The present invention discloses phthalazine isoxazole alkoxy derivatives, a preparation method thereof, a pharmaceutical composition, and a use thereof. The present invention provides a compound represented by Formula I, cis-trans isomers thereof, enantiomers thereof, diastereoisomers thereof, racemates thereof, solvates thereof, hydrates thereof, and pharmaceutically acceptable salts or prodrugs thereof. The compound has an excellent inverse agonist effect with respect to α5-GABA | 2021-01-14 |
20210009599 | THERAPEUTIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF - Compounds of Formula (I): | 2021-01-14 |
20210009600 | TRIAZOLO-PYRIMIDINE COMPOUNDS AND USES THEREOF - The present disclosure relates to novel triazolo-pyrimidine compounds targeting adenosine receptors (especially A1 and A2, particularly A2a). The present disclosure also relates to pharmaceutical compositions comprising one or more of the compounds as an active ingredient, and use of the compounds in the treatment of adenosine receptor (AR) associated diseases, for example cancer such as NSCLC, RCC, prostate cancer, and breast cancer. | 2021-01-14 |
20210009601 | MANUFACTURING PROCESS AND INTERMEDIATES FOR A PYRROLO[2,3-D]PYRIMIDINE COMPOUND AND USE THEREOF - The present invention relates to a manufacturing process and intermediates for preparing a crystalline or non-crystalline form of N-((1S,3S)-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)cyclobutyl)propane-1-sulfonamide. The present invention also relates to salt forms and pharmaceutical compositions comprising the crystalline form, and to methods for use of the compound prepared from a crystalline form in the treatment of various diseases. | 2021-01-14 |
20210009602 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT - This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a α5-containing GABA | 2021-01-14 |
20210009603 | SUBSTITUTED TETRAHYDROPYRANOINDOLES, DERIVATIVES THEREOF, AND THEIR METHODS OF SYNTHESIS AND USE - Disclosed herein are tetrahydropyranoindole compounds and derivatives thereof, as well as their methods of synthesis and use. The disclosed compounds may be synthesized by methods that utilize a cooperative hydrogen bond donor/Brønsted acid system. The disclosed compounds may be useful for treating a disease, disorder, or a symptom thereof in a subject in need thereof, such as pain, swelling, and joint stiffness. The disclosed compounds also may be useful for treating cell proliferative diseases and disorders such as cancer. | 2021-01-14 |
20210009604 | BIFURAN-IMIDE-BASED MATERIALS AND USES THEREOF - The invention concerns bifuran imide and methods of using same in the construction of furan-based oligomers and polymers. The furan-based systems are used for the construction of organic electronics. (formula) | 2021-01-14 |
20210009605 | CHROMIUM-MEDIATED COUPLING AND APPLICATION TO THE SYNTHESIS OF HALICHONDRINS - The present invention provides unified synthesis of the C1-C19 building blocks of halichondrins and analogs thereof using selective coupling of poly-halogenated nucleophiles in chromium-mediated coupling reactions. The present invention also provides a practical and efficient synthesis of C20-C38 building blocks of halichondrins and analogs thereof. Also provided herein are general methods of selective activation and coupling of poly-halogenated analogs with an aldehyde. The provided coupling reactions are selective for halo-enone and halo-acetylenic ketal over vinyl halide and halide attached to a sp hybridized carbon. The provided efficient selective coupling reactions can allow easy access to the C1-C19 building blocks and C20-C38 building blocks of halichondrins and analogs thereof with limited or no purification or separation of the intermediates. | 2021-01-14 |
20210009606 | Process for Preparation of Intermediates Used for the Synthesis of HIV Integrase Inhibitor - Provided herein is a process for the intermediates used for preparation of HIV Integrase Inhibitor such as Bictegravir, Dolutegravir, Cabotegravir or their pharmaceutically acceptable salts. | 2021-01-14 |
20210009607 | NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT - Novel compounds having D3 receptor antagonistic activity are provided. | 2021-01-14 |
20210009608 | AZA-BENZOTHIOPHENE COMPOUNDS AS STING AGONISTS - Compounds of general formula (I), and their pharmaceutically acceptable salts, wherein R | 2021-01-14 |
20210009609 | Compounds Useful in HIV Therapy - The invention relates to compounds of Formula (I), salts thereof, combinations, pharmaceutical compositions thereof, as well as therapeutic methods of treatment and prevention. | 2021-01-14 |
20210009610 | SILANE, RUBBER MIXTURE CONTAINING THE SILANE, AND VEHICLE TIRE HAVING THE RUBBER MIXTURE IN AT LEAST ONE COMPONENT - The invention relates to a silane, to a rubber mixture comprising the silane and to a vehicle tire comprising the rubber mixture in at least one component. | 2021-01-14 |
20210009611 | BENZYL COMPOUND - The purpose of the present invention is to provide a protecting group which improves the solubility of a compound having a functional group protected with the protecting group in an organic solvent and which is easily separated and purified after a reaction with avoiding solidification or insolubilization. Provided is a benzyl compound represented by Formula (1) where X | 2021-01-14 |
20210009612 | PHOSPHORUS IMIDAZOQUINOLINE AMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF - The invention provides novel phosphorus imidazoquinoline amine derivatives, having agonistic activities to Toll-like receptors (TLRs), in particular TLR7 and/or TLR8, pharmaceutical compositions thereof, and methods of treatment, reduction or prevention of certain diseases or conditions mediated by or associated with TLR7 and/or TLRS, e.g., cancer, graft rejection, autoimmunity, inflammation allergy, asthma, infection, sepsis, and immunodeficiency. | 2021-01-14 |
20210009613 | ARYLPHOSPHINE OXIDES FOR INHIBITING KINASE ACTIVITY - The present invention relates to an arylphosphine oxide having inhibitory effect on protein tyrosine kinases, a pharmaceutical composition containing the same, a preparation and a use thereof. Specifically, the present invention discloses a compound represented by formula (I), a pharmaceutically acceptable salt, crystal form, prodrug, metabolite, hydrate, solvate, stereoisomer or isotope derivative thereof, wherein X, Y, R | 2021-01-14 |
20210009614 | CRYSTALLINE FORMS - The invention relates to crystalline forms of 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidine-4-carbony]-amino}-3-phosphono-propionyl)-piperazine-1-carboxylic acid butyl ester hydrochloride, processes for the preparation thereof, pharmaceutical compositions comprising said crystalline forms, pharmaceutical compositions prepared from such crystalline forms and their use as a medicament, especially as a P2Y | 2021-01-14 |
20210009615 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES - A compound having the formula Ir(L | 2021-01-14 |
20210009616 | COMPOSITION AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME - A composition including a platinum-containing organometallic compound, a first compound, a second compound, and a third compound, and an organic light-emitting device including the same wherein the composition does not comprise iridium,
| 2021-01-14 |
20210009617 | COMPOSITIONS AND METHODS COMPRISING CONDUCTIVE METAL ORGANIC FRAMEWORKS AND USES THEREOF - Compositions and methods comprising metal organic frameworks (MOFs) and related uses are generally provided. In some embodiments, a MOF comprises a plurality of metal ions, each coordinated with at least one ligand comprising at least two sets of ortho-diimine groups arranged about an organic core. | 2021-01-14 |
20210009618 | A METHOD FOR PREPARING AN ACTIVATED LIGNIN COMPOSITION - The present invention relates to a method for preparing an activated lignin composition. In addition, the present invention also relates to a method for further processing the thus activated lignin composition in a method for preparing a lignin-phenol formaldehyde resin. Such a lignin-phenol formaldehyde resin can be used in the manufacturing of laminates by replacing the traditional synthetic phenol formaldehyde resin. | 2021-01-14 |
20210009619 | METHOD FOR PRODUCING ALLULOSE CRYSTALS - Allulose crystals are efficiently produced from an allulose syrup using seed crystals. | 2021-01-14 |
20210009620 | PURE HEPTASULFATED DISACCHARIDES HAVING IMPROVED ORAL BIOAVAILABILITY - Hypersulfated disaccharides with utility in asthma or asthma related disorders are disclosed. The heptasulfated disaccharides administered orally have comparable bioavailability to the intravenous administered dosage form. | 2021-01-14 |
20210009621 | AMINOCOUMARIN COMPOUNDS AND METHODS OF THEIR USE - Disclosed are aminocoumarin compounds, pharmaceutical compositions containing aminocoumarin compounds, and methods of their use, e.g., in the treatment of a Gram-negative bacterial infection. | 2021-01-14 |
20210009622 | LABELLED NUCLEOTIDES - The invention provides a nucleotide or nucleoside having a base attached to a detectable label via a cleavable linker, characterised in that the cleavable linker contains a moiety selected from the group comprising: Formula (I) (wherein X is selected from the group comprising O, S, NH and NQ wherein Q is a C | 2021-01-14 |
20210009623 | LABELLED NUCLEOTIDES - The invention provides a nucleotide or nucleoside having a base attached to a detectable label via a cleavable linker, characterised in that the cleavable linker contains a moiety selected from the group comprising: Formula (I) (wherein X is selected from the group comprising O, S, NH and NQ wherein Q is a C | 2021-01-14 |
20210009624 | [18F] FMAU LABELING FOR PET IMAGING OF CANCER PATIENTS - Provided herein are methods and labeling kits for synthesizing 2′-deoxy-2′-[ | 2021-01-14 |
20210009625 | DIASTEREOSELECTIVE SYNTHESIS OF PHOSPHATE DERIVATIVES - The present invention provides a method for the preparation of intermediates useful in the synthesis of gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate. It also provides a method of preparing gemcitabine-[phenyl-benzoxy-L-alaninyl)]-phosphate. | 2021-01-14 |
20210009626 | SOLID-STATE FORMS OF REGADENOSON, THEIR USE AND PREPARATION - The invention relates to a crystalline methanol or dimethyl sulfoxide solvated form of regadenoson and an anhydrous polymorph of regadenoson. The invention is also directed to the preparation of the methanol or dimethyl sulfoxide solvated and anhydrous solid-state forms of regadenoson. In particular, the invention relates to the preparation of the anhydrous polymorph of regadenoson in a stable form from the dimethyl sulfoxide solvated form of regadenoson, which preparation is purifiable and scalable. | 2021-01-14 |
20210009627 | CYCLIC DINUCLEOTIDE COMPOUNDS CONTAINING 2-AZA-HYPOXANTHINE OR 6H-PYTAZOLO[1,5-D][1,2,4]TRIZAIN-7-ONE AS STRING AGONISTS - Compounds of formula I, wherein Base, R | 2021-01-14 |
20210009628 | Beta-D-2'-DEOXY-2'-Alpha-FLUORO-2'-Beta-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTI- TUTED PURINE NUCLEOTIDES FOR HCV TREATMENT - A compound of the structure: | 2021-01-14 |
20210009629 | RIBONUCLEIC ACIDS WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS - Disclosed are messenger RNA molecules and related compositions incorporating a 4′-thio modification in the furanose ring of at least one nucleotide residue, and methods of using these mRNAs to produce an encoded therapeutic protein in vivo and to treat or prevent diseases or disorders. In certain embodiments, the 4′-thio modified mRNA provides for enhanced stability and/or reduced immunogenicity in in vivo therapies. | 2021-01-14 |
20210009630 | CYCLIC DINUCLEOTIDES AS STING AGONISTS - Disclosed are compounds, compositions and methods for treating of diseases, syndromes, or disorders that are affected by the modulation of STING. Such compounds are represented by Formula (I) as follows: wherein B | 2021-01-14 |
20210009631 | SOLID PHASE SYNTHESIS OF ACYLATED PEPTIDES - The present invention relates to methods and compounds for the solid phase synthesis of peptides carrying a substituent at an amino group of an amino acid side chain. | 2021-01-14 |
20210009632 | METHODS OF PURIFYING MONOMERIC MONOCLONAL ANTIBODIES - In certain embodiments, the present invention provides a method of purifying a monomeric monoclonal antibody from a mixture which comprises the monomeric monoclonal antibody and one or more contaminants, comprising: a) subjecting the mixture to cation exchange chromatography (CEX) matrix, wherein the monomeric monoclonal antibody binds to the CEX matrix; b) contacting the CEX matrix with a wash solution at a pH which is between about 7 and about 7.8; c) eluting the monomeric monoclonal antibody from the CEX matrix into an elution solution, thereby purifying the monomeric monoclonal antibody. | 2021-01-14 |
20210009633 | BACTERIAL COLICIN-IMMUNITY PROTEIN PROTEIN PURIFICATION SYSTEM - Provided herein are compositions and methods for protein purification. | 2021-01-14 |
20210009634 | FULL FLOW-THROUGH PROCESS FOR PURIFYING RECOMBINANT PROTEINS - The present invention concerns a method for purifying a protein comprising in a continuous mode: one filtration step involving the use of at least one chelating agent, an exchanging step involving the use of at least one diafiltration membrane, and a polishing step involving the use of a combination of membrane adsorbers, wherein two membrane adsorbers of said combination are orthogonal in terms of mechanism of action. | 2021-01-14 |
20210009635 | HYBRID LIGAND, HYBRID BIOMIMETIC CHROMEDIA AND PREPARING METHOD AND USE THEREOF - This invention relates to a hybrid ligand, a hybrid biomimetic chromedia and a preparing method and a use thereof, wherein the hybrid biomimetic chromedia takes hydrophilic porous microsphere as a substrate in chromatography, activated with allyl bromide and undergoing bromo-alcoholization with N-bromosuccinimide, then coupled with the hybrid ligands. The sequence of the hybrid ligand is phenylalanine-tyrosine-glutamine-5-aminobenzimidazole. The hybrid biomimetic chromedia has both of the two functional groups of phenylalanine-tyrosine-glutamine tripeptide and aminobenzimidazole, while maintaining the high antibody selectivity of polypeptide ligand, hydrophobic electric charge inductive ligand is introduced to achieve more moderate elution requirement, realizing effective antibody separation. | 2021-01-14 |
20210009636 | NOVEL ARID5A PEPTIDE INHIBITORS - AT-rich interactive domain-containing protein 5a (Arid5a) inhibitors can include mid-sized peptides (peptides having less than 15 amino acids) that inhibit the activity of Arid5a. The peptides include the sequence of SEQ ID NO: 1. In an embodiment, the Arid5a peptide inhibitors can include a peptide having a sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO:3, and SEQ ID NO:4. The Arid5a peptide inhibitors can be useful for experimental investigation and treating a disease or disorder, such as, inflammation, diseases associated with inflammation, cancer, and autoimmune disease. | 2021-01-14 |
20210009637 | BIOMIMETIC PEPTIDES DERIVED FROM BIOLOGICAL SOURCE AND THEIR USES IN RETARDING AGING AND IMPROVING SKIN - The present disclosure provides peptides comprising a motif having four amino acids, wherein each of the amino acids at N-terminus and C-terminus of the sequence independently has a same or different positively charged side chain, and each of the amino acids between the N-terminal and C-terminal of the motif independently has a same or different uncharged side chain. The present disclosure surprisingly found that these peptides have advantageous effects in inhibiting or decreasing collagen breakdown, increasing production of collagen, elastin and/or hyaluronic acid, retarding aging, improving skin and inhibiting inflammation. | 2021-01-14 |
20210009638 | PEPTIDE INHIBITORS OF INTERLEUKIN-23 RECEPTOR AND THEIR USE TO TREAT INFLAMMATORY DISEASES - The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases. | 2021-01-14 |
20210009639 | INSULIN LIKE GROWTH FACTOR BINDING PROTEIN BIOACTIVE PEPTIDE FRAGMENTS - Described herein are isolated peptides, compositions comprising the same, and methods of using such peptides or compositions in the treatment of depression, central nervous system disorders, and neurodevelopmental disorders. | 2021-01-14 |
20210009640 | COMPOSITIONS COMPRISING HIV ENVELOPES TO INDUCE HIV-1 ANTIBODIES - The invention is directed to modified HIV-1 envelopes, compositions comprising these modified envelopes and methods of using these modified HIV-1 envelopes to induce immune responses. | 2021-01-14 |
20210009641 | EXPRESSION OF PNEUMOCOCCAL SURFACE PROTEIN A (PSPA) - The present invention relates to expression of Pneumococcal Surface Protein A (PspA). The invention represents an advancement in the field of genetic engineering and vaccine technology. The invention discloses expression vectors and recombinant host cells for expression of truncated PspA peptide. The invention also discloses vaccine compositions comprising the truncated peptides as carrier protein. | 2021-01-14 |
20210009642 | A QUANTITATIVE ENZYME-LINKED IMMUNOASSAY (ELISA) TO APPROXIMATE COMPLEMENT FIXING ANTIBODY TITERS IN SERUM FROM PATIENTS WITH COCCIDIOIDOMYCOSIS - Coccidioidomycosis is most often diagnosed serologically and the quantitative complement-fixing antibody test (CF) is considered prognostically useful. Because CF is complex, labor-intensive, and poorly standardized, an enzyme-linked immunoassay (ELISA) alternative would be attractive. The present invention features an antibody-binding domain that is restricted to a 200 amino acid recombinant peptide of the known antigen responsible for CF activity. Overlapping truncations of this peptide do not bind CF antibodies, suggesting that the responsible epitope(s) are conformational. Further, anchoring the antigenic peptide to the ELISA plate by means of a C-terminal tag instead of allowing the peptide to randomly adhere to the plastic plate improves sensitivity of antibody detection by one to two logs in different sera. The newly developed ELISA shows a significant quantitative correlation with CF. This ELISA shows potential as the basis for a new quantitative assay for coccidioidal antibodies. | 2021-01-14 |
20210009643 | CHIMERIC INHIBITOR MOLECULES OF COMPLEMENT ACTIVATION - The present invention relates to novel chimeric molecules of ficolin-associated polypeptides, such as fusion polypeptides for the use in the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombotic or coagulopathic related diseases. The present invention further relates to nucleic acid molecules encoding such fusion polypeptides, vectors and host cells used in the production of the fusion polypeptides. | 2021-01-14 |
20210009644 | SECRETORY PROTEIN - The disclosure of the present application relates to a secretory deleted split hand/split foot 1 (sDSS1) protein, the amino acid sequence thereof, the nucleic acid sequence thereof, and the applications of the same. The sDSS1 protein is a secretory protein from higher primate, and can be detected in human serum and cerebral spinal fluid (CSF). The sDSS1 protein can form conjugate with oxidized protein under nonenzymatic condition or with amyloid-beta (Aβ) polypeptide to reduce formation of Aβ oligomer. The addition of sDSS1 protein to culture medium can shield the cytotoxicity induced by oxidized protein, Aβ oligomer, amylin oligomer and glycosylated protein, so as to protect the cells against these toxoproteins. The sDSS1 protein can prolong survival time of senescence-accelerated mice significantly. The protein can be used to prevent and treat the diseases induced by oxidized protein, glycated protein, Aβ protein accumulation, amylin protein accumulation or excessive formation or accumulation of other pathogenic proteins with similar features, and has important potential in biological medicine. | 2021-01-14 |
20210009645 | C-terminal CDNF and MANF fragments, pharmaceutical compositions comprising same and uses thereof - The present invention provides a C-terminal CDNF fragment sequence or a sequence which has at least 80% homology or sequence identity to said sequence. The C-terminal CDNF fragment protects ER stressed neurons, motoneurons and dopaminergic neurons and the fragment is capable of penetrating neuronal cell membrane as well as the blood-brain-barrier. The present invention further provides said fragment and pharmaceutical compositions comprising said fragment for use in treatments of degenerative diseases and disorders including central nervous system diseases, diabetes and retinal disorders. The present invention is also providing a C-terminal MANF fragment sequence or a sequence which has at least 80% homology or sequence identity to the said sequence and pharmaceutical compositions comprising said MANF fragment for use in the treatment of degenerative diseases and disorders including central nervous system diseases, diabetes and retinal disorders. | 2021-01-14 |
20210009646 | VGLL4 WITH UCP-1 CIS-REGULATORY ELEMENT AND METHOD OF USE THEREOF - Provided is a polynucleotide, including a cis-regulatory element and a nucleotide sequence encoding a vestigial like 4 protein, wherein the cis-regulatory element includes an uncoupling protein 1 enhancer and an uncoupling protein 1 promoter. Also provided is a viral vector including said polynucleotide. Also provided is a method of transfecting a cell or a subject with said polynucleotide or said viral vector. | 2021-01-14 |
20210009647 | A POLYPEPTIDE EXHIBITING GRANULOCYTE-COLONY STIMULATING FACTOR ACTIVITY - The present disclosure relates to a polypeptide exhibiting granulocyte-colony stimulating factor activity. The polypeptide comprises at least one non-native cysteine residue at a site selected from the group consisting of T | 2021-01-14 |
20210009648 | PEPTIDES FOR TREATMENT OF DIABETES - The present disclosure concerns agents and their use in the treatment of endocrine, nutritional and/or metabolic diseases in a mammal. The disclosure furthermore concerns novel peptides. | 2021-01-14 |
20210009649 | INTRON FOR INCREASING EXPRESSION LEVEL OF RHNGF - A gene combination for expressing recombinant human nerve growth factor (rhNGF) includes an rhNGF precursor gene and an intron. The intron can have a nucleotide sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2. A eukaryotic expression vector for rHNGF expression including the gene combination, a CHO cell including the eukaryotic expression vector, and methods for preparing rhNGF using the gene combination, the expression vector, and the CHO cell are also disclosed. | 2021-01-14 |
20210009650 | MODIFIED FIBROBLAST GROWTH FACTORS AND USES THEREOF - Described herein are modified fibroblast growth factors (FGFs), pharmaceutical compositions, formulations, and medicaments that include such modified FGFs, and methods of using such modified FGFs to treat mammalian diseases, disorders, or conditions. | 2021-01-14 |
20210009651 | USE OF IL-34 TO TREAT RETINAL INFLAMMATION AND NEURODEGENERATION - Methods are provided for protecting a subject from retinal degeneration, and/or treating uveitis, retinitis or chorioretinitis in a subject. The methods include selecting a subject with uveitis, retinitis, or chorioretinitis and/or in need of protection from retinal degeneration; and administering locally to the eye of the subject a therapeutically effective amount of: (a) a polypeptide comprising amino acids 1-182 of an interleukin (IL)-34, a variant of IL-34, or an Fc fusion protein of IL-34, wherein the polypeptide, variant, or Fc fusion protein is i) anti-inflammatory or ii) neuroprotective; or (b) a nucleic acid molecule encoding the polypeptide, variant, or Fc fusion protein. A pharmaceutical composition for use in any of the disclosed methods is also provided. | 2021-01-14 |
20210009652 | USE OF ICOS-BASED CARS TO ENHANCE ANTITUMOR ACTIVITY AND CAR PERSISTENCE - The present invention provides compositions and methods for treating cancer in a human. The invention includes administering a genetically modified Th17 cell to express a CAR having an antigen binding domain, a transmembrane domain, and an ICOS intracellular signaling domain. | 2021-01-14 |
20210009653 | LENTIVIRAL VECTORS FOR REGULATED EXPRESSION OF A CHIMERIC ANTIGEN RECEPTOR MOLECULE - The invention relates to the regulated expression of a chimeric antigen receptor (CAR) within a lentiviral vector. The CAR comprises a hook-binding domain that interacts with a hook, preferably encoded by the same lentiviral vector, which prevents proper processing and release of the CAR to the cell membrane. The invention encompasses vectors, methods of making the vectors, and methods of using them, including medicinal uses. The vectors can be used for administration to humans to induce immune responses and to treat cancers and tumors. | 2021-01-14 |
20210009654 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. | 2021-01-14 |
20210009655 | METHODS AND COMPOSITIONS FOR GENERATING AN IMMUNE RESPONSE BY INDUCING CD40 AND PATTERN RECOGNITION RECEPTOR ADAPTERS - Provided are methods for activating an antigen-presenting cell and eliciting an immune response by inducing an inducible pattern recognition receptor adapter, or adapter fragment, and CD40 activity. Also provided are nucleic acid compositions comprising sequences coding for chimeric proteins that include an inducible CD40 peptide and an inducible pattern recognition receptor adapter or adapter fragment. | 2021-01-14 |
20210009656 | C-TERMINALLY FUSED TNF FAMILY LIGAND TRIMER-CONTAINING ANTIGEN BINDING MOLECULES - The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) one Fab domain capable of specific binding to a target cell antigen, (b) a Fc domain composed of a first and a second subunit capable of stable association, and (c) a first polypeptide comprising two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and a second polypeptide comprising one ectodomain of said TNF ligand family member or a fragment thereof, wherein the first polypeptide is fused at its N-terminus to the C-terminus of one of the subunits of the Fc domain and wherein the second polypeptide is fused at its N-terminus to the C-terminus of the other subunit of the Fc domain, wherein the TNF family ligand trimer-containing antigen binding molecule is monovalent for the binding to the target cell antigen. | 2021-01-14 |
20210009657 | SOLUBLE FGFR3 DECOYS FOR TREATING SKELETAL GROWTH DISORDERS - The invention features soluble FGF decoy polypeptides and fusion polypeptides comprising an FGF decoy polypeptide linked to a heterologous polypeptide, such as an aggrecan binding protein. Both soluble FGF decoy polypeptides and fusion polypeptides can be used to prevent or treat skeletal disorders, such as achondroplasia. | 2021-01-14 |
20210009658 | IL-15/IL-15RALPHA BASED CONJUGATES PURIFICATION METHOD - The present invention relates to a method for preparing a composition comprising monomeric conjugates from a sample, said conjugate comprising (a) a polypeptide comprising the amino acid sequence of interleukin 15 or derivatives thereof, and (b) a polypeptide comprising the amino acid sequence of the sushi domain of IL-15Rα or derivatives thereof; wherein said method comprises the use of anion-exchange chromatography followed by a hydrophobic interaction chromatography; and to a pharmaceutical composition which can be obtained by such a method. | 2021-01-14 |
20210009659 | MULTIVALENT HETEROMULTIMER SCAFFOLD DESIGN AND CONSTRUCTS - Provided herein are multifunctional heteromer proteins. In specific embodiments is a heteromultimer that comprises: at least two monomeric proteins, wherein each monomeric protein comprises at least one cargo polypeptide, attached to a transporter polypeptide, such that said monomeric proteins associate to form the heteromultimer. These therapeutically novel molecules comprise monomers that function as scaffolds for the conjugation or fusion of therapeutic molecular entities resulting in the creation of bispecific or multivalent molecular species. | 2021-01-14 |
20210009660 | RECOMBINANT IMMUNOGLOBULIN HEAVY CHAINS COMPRISING A SORTASE CONJUGATION LOOP AND CONJUGATES THEREOF - The disclosure describes a recombinant immunoglobulin heavy chain comprising a sortase conjugation loop, methods for conjugating and/or labeling such recombinant immunoglobulin heavy chains by use of the enzyme sortase and to the conjugates/labeled products obtained via the method. | 2021-01-14 |
20210009661 | HIV Binding Agents - This disclosure relates to binding agents with specificity for HIV and to methods for using the same to treat, pre-vent and/or ameliorate HIV infection and/or AIDS. | 2021-01-14 |
20210009662 | ANTIBODY-MEDIATED NUTRALIZATION OF CHIKUNGUNYA VIRUS - The present disclosure is directed to antibodies binding to and neutralizing Chikungunya virus (CHIKV) and methods for use thereof. | 2021-01-14 |
20210009663 | ANTIBODIES THAT BIND ZIKA VIRUS ENVELOPE PROTEIN AND USES THEREOF - Isolated monoclonal antibodies which bind to Zika virus envelope protein and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies. | 2021-01-14 |
20210009664 | CELLULAR FACTORS INVOLVED IN THE CYTOTOXICITY OF STAPHYLOCOCCUS AUREUS LEUKOCIDINS: NOVEL THERAPEUTIC TARGETS - The present invention relates to methods for treating and preventing | 2021-01-14 |
20210009665 | ANTIBODIES TO AMYLOID BETA - Antibody for human amyloid beta. Antibody selectively binds human amyloid beta 42 peptide over human amyloid beta 40 peptide. Antibodies specific for amyloid beta 42 as therapeutic agents for binding amyloid beta 42 peptide and treating conditions associated with amyloidosis, such as Alzheimer's disease. | 2021-01-14 |
20210009666 | HUMANIZED TAU ANTIBODIES IN ALZHEIMER'S DISEASE - The present invention is in the fields of biochemistry, molecular biology, and Alzheimer's disease diagnosis, prevention, and treatment. Provided herein are humanized antibodies against human tau that are capable of discriminating between normal (healthy) and pathological (disease-associated) tau. | 2021-01-14 |
20210009667 | ANTI-NEUROTENSIN LONG FRAGMENT ANTIBODIES AND USES THEREOF - The present invention relates to a neutralising antibody which is capable of binding to neurotensin with high affinity. The antibody of the present invention neutralises the activity of neurotensin, in particular the oncogenic activities of neurotensin. In particular, the present invention relates to a neutralising antibody which binds to the human neurotensin long fragment, and having a heavy chain variable region which comprises a H-CDR1 region having at least 90% of identity with SEQ ID NO:2, a H-CDR2 region having at least 90% of identify with SEQ ID NO:3 and a H-CDR3 region having at least 90% of identity with SEQ ID NO:4; and a light chain variable region comprising a L-CDR1 region having at least 90% of identity with SEQ ID NO:6, a L-CDR2 having at least 90% of identity with SEQ ID NO:7 and a L-CDR3 region having at least 90% of identity with SEQ ID NO:8. The present invention also provides the use of such antibodies in the treatment of cancer. | 2021-01-14 |
20210009668 | NOVEL ANTI-TROPONIN T ANTIBODIES - The present invention relates to improved variant monoclonal antibodies binding to cardiac troponin T and having a better KD than the monoclonal antibody 12.1A11.11-7, produced by hybridoma clone 7.1 A 12.2-22 (ECACC 89060901) as deposited with European Collection of Animal Cell Cultures, GB. 5 | 2021-01-14 |
20210009669 | FUSION PROTEIN CONSTRUCTSCOMPRISING ANTI-C3d ANTIBODY AND FACTOR H - Provided herein are fusion protein constructs that can bind a complement-associated antigen, comprising a targeting moiety and a complement modulator protein, or a fragment thereof or a variant thereof. The targeting moiety is an antibody or an antigen binding fragment thereof, in some examples. Further provided are methods of using the fusion protein constructs, for example, in treating complement mediation conditions. | 2021-01-14 |
20210009670 | NUCLEIC ACID MOLECULES AND APPLICATIONS THEREOF IN HUMAN ANTIBODY - Nucleic acid molecules include immunoglobulin genes or parts of immunoglobulin genes. The nucleic acid molecules includes the IgM gene (IgHCμ) and IgM switch region (Sμ). The sequences of the Sμ and the IgHCμ are both derived from a transgenic host animal. In this invention, human antibodies are directly generated and no humanization process is required, and the human antibody druggability is increased. The transgenic human antibody mouse has normal early B | 2021-01-14 |
20210009671 | COMPOUNDS AND METHODS FOR TREATING PAIN - This disclosure provides novel methods and dosage regimens for use in treating pain with a binding molecule comprising comprising an NGF antagonist domain and a TNFα antagonist domain; wherein the NGF antagonist domain is an anti-NGF antibody, or antigen-binding fragment thereof; and wherein the TNFα antagonist domain comprises a soluble, TNFα-binding fragment of a TNFR. | 2021-01-14 |
20210009672 | METHODS OF TREATING OR PREVENTING LIVER FIBROSIS WITH INHIBITION OF ACTIVINS A & B - The invention relates to methods to modulate liver fibrosis in a subject by administering an activin inhibitor to the subject. In embodiments of the invention, the activin inhibitor can be an activin A antibody or fragment thereof, an activin B antibody or fragment thereof or both an activin A and activin B antibody or fragments thereof. The methods described can be used to treat or modulate liver fibrosis caused by several diseases or disorders including: autoimmune hepatitis, biliary obstruction, iron overload nonalcoholic fatty liver disease, which includes nonalcoholic fatty liver and nonalcoholic steatohepatitis, viral hepatitis B, hepatitis C, alcoholic liver disease or the long-term consumption of alcohol. | 2021-01-14 |
20210009673 | METHODS FOR REGULATING BREAST CANCERS - Disclosed are methods for altering cellular characteristics that pertain to cancer and for slowing, halting, or reversing the transformation of cells to cancerous phenotypes in general or the transformation of cells from more benign forms to less benign forms of cancer, and in particular, breast cancer. | 2021-01-14 |